NEWS
- Pharma & Biotech News #PharmaBuzz
- Weekly News Recap #Phispers
- Recent Product Approvals #GreenLight
- Quality Compliance Alerts #Warning!
- All News #Library
DRUGS & DEVELOPMENTS
MARKET INTEL by PharmaCompass
Create content with us, ask us
By PharmaCompass
2019-01-10
Impressions: 162 Article
In the United States, drugmakers greeted 2019 with price increases on more than 250 prescription drugs, including the world’s top-selling medicine, Humira. However, the pace of price increases this year was slower than last year.
The drug industry has been under tremendous pressure exerted by the Trump administration to hold prices in the world’s most expensive pharmaceutical market.
During a meeting of his cabinet at the White House, the US President Donald Trump said last week that he expects to see a tremendous decrease in drug prices. He said this while being fully aware that late last year nearly 30 drugmakers had notified California agencies they plan to raise list prices of their drugs. However, not all of those increases have been announced yet.
The price increases, so far, have been relatively modest, though some are particularly high, including on some generics. Overall, price increases continue to exceed inflation.
More than three dozen drugmakers raised the prices on hundreds of medicines in the US, according to an analysis from Rx Savings Solutions. The average increase was 6.3 percent, according to this analysis, including increases on different doses for the same drug.
Allergan had the most increases of more than 9 percent. The company raised the price of 51 products — 27 by about 9.5 percent and another 24 by about 4.9 percent. The increases covered more than half of its portfolio, from an extended-release version of its Alzheimer’s drug Namenda to dry-eye treatment Restasis.
AbbVie Inc increased the list price of its blockbuster rheumatoid arthritis treatment Humira by 6.2 percent. Humira is poised to record about US$ 20 billion in sales in 2018.
The overall number of price increases was down by around a third from last year, when drugmakers raised prices on more than 400 medicines.
The PharmaCompass Newsletter – Sign Up, Stay Ahead
Feedback, help us to improve. Click here
Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0
“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”
